

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE


Single Technology Appraisal

Polihexanide eye drops for treating acanthamoeba keratitis in people 12 years and over [ID6497]

Final Stakeholder List

Provisional Consultees	Provisional Commentators (no right to submit or appeal)
Company	General
SIFI S.p.a. (polihexanide)	All Wales Therapeutics and Toxicology
	Centre
Patient/carer groups	Allied Health Professionals Federation
Eyecare Trust	Board of Community Health Councils in
Fight for Sight	Wales
Guide Dogs	British National Formulary
Macular Society	Care Quality Commission
 National Federation of the Blind of the 	Department of Health - Northern Ireland
UK	Healthcare Improvement Scotland
Royal National Institute of Blind	Medicines and Healthcare products
People (RNIB)	Regulatory Agency
SeeAbility	 National Association of Primary Care
Sense	National Pharmacy Association
South Asian Health Foundation	NHS Confederation
Specialised Healthcare Alliance	NHS Wales Joint Commissioning
Thomas Pocklington Trust	Committee
- Themas i demington made	Scottish Medicines Consortium
Healthcare professional groups	Wales Council for the Blind
Association of Optometrists	Welsh Government
British and Irish Orthoptic Society	• Weish Government
British Geriatrics Society	Comparator companies
British Ophthalmic Anaesthesia	Thorton & Ross Ltd (propamidine)
Society (BOAS)	Thorton & Ross Eta (propamiane)
College of Optometrists	Relevant research groups
 Neonatal and Paediatric Pharmacists 	 Cochrane Eyes and Vision Group
Group	Eye Hope
Optical Confederation	Genomics England
Royal College of General Practitioners	 Institute of Ophthalmology, University
Royal College of Nursing	College London
Royal College of Ophthalmologists	MRC Clinical Trials Unit
Royal College of Paediatrics & Child	 National Eye Research Centre
Health	National Institute for Health Research
Royal College of Pathologists	National Institute for Health Research
Royal College of Physicians	Biomedical Research Centre for

Final stakeholder list for the evaluation of polihexanide eye drops for treating acanthamoeba keratitis in people 12 years and over [ID6497] Issue date: April 2025



Provisional Consultees	Provisional Commentators (no right to submit or appeal)
 Royal Pharmaceutical Society Royal Society of Medicine UK Clinical Pharmacy Association Others Department of Health and Social Care NHS England 	Ophthalmology, Moorfields Eye Hospital and UCL Institute of Ophthalmology Associated Public Health groups Public Health Wales UK Health Security Agency

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

Definitions:

Consultee or commentator stakeholders are provisional until a signed Confidentiality Agreement & Undertaking form is submitted to NICE at the evaluation stage. Participating stakeholders will be listed on the project information page for the evaluation.

Consultees

Organisations that accept an invitation to participate in the evaluation; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Draft Guidance (FDG).

All non-company consultees are invited to submit a statement relevant to the group they are representing, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Draft Guidance (FDG).


Commentators

Organisations that engage in the evaluation process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations

Final stakeholder list for the evaluation of polihexanide eye drops for treating acanthamoeba keratitis in people 12 years and over [ID6497]

Issue date: April 2025





and they receive the FDG for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC]); other groups (for example, the NHS Confederation and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts.